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Abstract Dystroglycan is a cytoskeleton-linked extracellular
matrix receptor expressed in many cell types. Dystroglycan is
composed of K- and L-subunits which are encoded by a single
mRNA. Using a heterologous mammalian expression system, we
provide the first biochemical evidence of the K/L-dystroglycan
precursor propeptide prior to enzymatic cleavage. This 160 kDa
dystroglycan propeptide is processed into K- and L-dystroglycan
(120 kDa and 43 kDa, respectively). We also demonstrate that
the precursor propeptide is glycosylated and that blockade of
asparagine-linked (N-linked) glycosylation did not prevent the
cleavage of the dystroglycan precursor peptide. However,
inhibition of N-linked glycosylation results in aberrant traffick-
ing of the K- and L-dystroglycan subunits to the plasma
membrane. Thus, dystroglycan is synthesized as a precursor
propeptide that is post-translationally cleaved and differentially
glycosylated to yield K- and L-dystroglycan.
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1. Introduction
Dystroglycan is a recently characterized high-a⁄nity recep-
tor for several extracellular matrix components, including
laminin [1^5] and perlecan [6]. The K- and L-subunits of dys-
troglycan are thought to arise from post-translational cleav-
age of a single dystroglycan propeptide. K-Dystroglycan, a
peripheral membrane protein, interacts with laminin in the
basal lamina and L-dystroglycan. In turn, L-dystroglycan,
which crosses the membrane bilayer, associates with dystro-
phin and is thereby connected to the actin cytoskeleton. In
addition to providing a structural linkage between the intra-
cellular and extracellular regions of a cell, the dystroglycans
are involved in agrin- and laminin-induced acetylcholine re-
ceptor clustering at the neuromuscular junctions, morphogen-
esis, early development and the pathogenesis of muscular dys-
trophies (for review, see [7]).
Dystroglycan was originally identi¢ed as a component of
the dystrophin^glycoprotein complex, or DGC, which is a
multisubunit group of proteins and glycoproteins resident in
the sarcolemma of striated muscle. The DGC is comprised of
dystrophin, a large cytoskeletal protein which binds F-actin;
K- and L-dystroglycan which bind the G domain of laminin-2
and the C-terminal cysteine-rich region of dystrophin, respec-
tively; the syntrophins; the sarcoglycan subcomplex, which is
composed of four tightly associated glycoproteins named K-,
L-, Q- and N-sarcoglycan, and sarcospan (for review, see [8,9]).
Functionally, the DGC stabilizes the muscle ¢ber sarcolemma
against the considerable forces of contraction by linking the
extracellular matrix and the actin cytoskeleton. The central
role of the DGC in normal muscle function is underscored
by discoveries that mutations in several components of the
DGC give rise to distinct muscle disorders. Primary mutations
in dystrophin, laminin-2 or any of sarcoglycans cause Duch-
enne muscular dystrophy (DMD, [10]), congenital muscular
dystrophy (CMD, [11,12]) and limb-girdle muscular dystrophy
(LGMD), respectively (for review, see [13]).
To date, there are no reports of dystroglycan mutations
that cause muscular dystrophy in humans. However, dystro-
glycan structure and function are perturbed in many types of
muscular dystrophy. K- And L-dystroglycan are greatly re-
duced from the sarcolemma in muscle from patients with
DMD. In LGMD patients, K- and L-dystroglycan are local-
ized to the sarcolemma, but K-dystroglycan is not appropri-
ately anchored to the muscle plasma membrane [14^16]. In
both of these cases, perturbation of the dystroglycan complex
results in a break in the structural connection between the
extracellular matrix and the cytoskeleton. Interestingly, tar-
geted deletion of the dystroglycan gene in mice results in an
early embryonic lethality due to a defect in Reichert’s mem-
brane [17]. Therefore, dystroglycan may function as an essen-
tial gene early in the development of humans prior to any
assumed critical role in muscle function. Most interestingly,
K-dystroglycan has been shown to act as a Schwann cell re-
ceptor for Mycobacterium leprae [18] and has been identi¢ed
as the receptor for lymphocytic choriomeningitis virus and the
lassa fever virus [19].
We recently developed a heterologous cell expression sys-
tem in order to determine how primary defects in components
of the DGC a¡ect the assembly and function of this complex
[20]. We ¢rst applied this in vivo methodology to examine the
biosynthesis and processing of the sarcoglycan complex [20].
We reported that the molecular defect underlying LGMD is
due to aberrant assembly and tra⁄cking of the entire sarco-
glycan complex [20]. We now apply this methodology to ex-
amine the importance of post-translational modi¢cations to
the processing and membrane localization of the dystroglycan
complex.
K- And L-dystroglycan are tightly associated via non-cova-
lent interactions, and together they form a direct link between
the extracellular matrix protein laminin-2 and the cytoskeletal
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 1 9 5 - 9
*Corresponding author. Howard Hughes Medical Institute, Univer-
sity of Iowa College of Medicine, 400 Eckstein Medical Research
Building, Iowa City, IA 52242, USA. Fax: (1)-319-335 6957.
E-mail: kevin-campbell@uiowa.edu
Abbreviations: CHO, Chinese hamster ovary; DGC, dystrophin^gly-
coprotein complex; DIC, di¡erential interference contrast; DMD,
Duchenne muscular dystrophy; LGMD, limb-girdle muscular dystro-
phy; N-linked, asparagine-linked
FEBS 23340 10-2-00 Cyaan Magenta Geel Zwart
FEBS 23340 FEBS Letters 468 (2000) 79^83
protein dystrophin [1^4]. Several studies suggest that K-dys-
troglycan is a sialylated mucin-type glycoprotein and that this
modi¢cation is necessary for laminin binding [21^23]. In ad-
dition, K-dystroglycan has several conserved sites for aspara-
gine-linked (N-linked) glycosylation and glycosaminoglycan
addition (for review, see [24]). The primary sequence of K-
dystroglycan predicts a molecular mass of 72 kDa; however,
K-dystroglycan in mammalian skeletal muscle is 156 kDa [1],
140 kDa in cardiac muscle [25] and 120 kDa in brain and
peripheral nerve [26,27]. Therefore, K-dystroglycan undergoes
signi¢cant post-translational modi¢cations in a tissue-speci¢c
manner and these specialized modi¢cations likely a¡ect dys-
troglycan’s function. In fact, dystroglycan is expressed in
many cell types, suggesting that dystroglycan contributes to
multiple cellular functions in addition to its role in skeletal
muscle.
The dystroglycans are thought to be produced by a single
mRNA [28]. However, there is currently no reported evidence
demonstrating the presence of a dystroglycan precursor pro-
peptide prior to cleavage. Using a heterologous mammalian
expression system, we are able to provide the ¢rst evidence for
an K/L-dystroglycan peptide. We also show that cleavage of
the precursor propeptide into its respective K- and L-subunits
can occur in the absence of N-linked glycosylation. Membrane
localization of K- and L-dystroglycan was dependent on prop-
er glycosylation. Furthermore, we show that this mammalian
cell system is an appropriate model for examining the syn-
thesis and post-translational processing of dystroglycan.
2. Materials and methods
2.1. cDNA expression construct
The rabbit dystroglycan expression construct was prepared by clon-
ing an EcoRI fragment containing the complete cDNA for rabbit
dystroglycan [28] into the EcoRI site of pcDNA3 (Pharmacia). Con-
structs were screened for directionality by restriction enzyme analysis,
and sequenced by the DNA Core Facility at the University of Iowa.
2.2. Cell culture and transient transfection by electroporation
Chinese hamster ovary (CHO) cells were maintained in K-minimal
Eagle’s medium supplemented with nucleosides and 10% fetal bovine
serum. Electroporation was performed as described previously [20].
Optimal expression was achieved using approximately 5 Wg of cesium
chloride gradient-puri¢ed plasmid DNA.
2.3. Antibodies
Monoclonal antibody speci¢c to L-dystroglycan (8D5) was a gen-
erous gift of Dr. Louise V.B. Anderson (Newcastle General Hospital,
Newcastle upon Tyne, UK) [29]. Sheep 005 antibody against K-dys-
troglycan has been described previously [30]. Polyclonal sheep anti-
bodies speci¢c to K-dystroglycan (Sheep 172) were raised by injection
of three peptides: CAAKNHIDRVDAWVGTYFEVK, CAAKIPSD-
TFYDK and CAAKSWVQFNSNSQLMYGLPDSSHVGK, which
correspond to amino acids 500^517, 517^526 and 548^574, respec-
tively, of the rabbit dystroglycan sequence. Sheep 172 antibodies
were a⁄nity-puri¢ed using Immobilon-P (Millipore, Burlington,
MA, USA) strips containing the bovine serum albumin (BSA)-
coupled peptides CAAKNHIDRVDAWVGTYFEVK and CAAKIP-
SDTFYDK.
2.4. Enzymatic deglycosylation
Cell lysates (20 Wg) were treated with PNGaseF as recommended by
the manufacturer (Oxford Glycosystems), and analyzed by immuno-
blotting with the 8D5 monoclonal antibody speci¢c to L-dystroglycan
and the Sheep 172 polyclonal antibody speci¢c to K-dystroglycan.
2.5. Tunicamycin treatment
Transfected cells were allowed to recover and adhere to culture
dishes or glass cover slips for 1 h. The media were then exchanged
with normal complete media or, where indicated, media supplemented
with 10 Wg/ml tunicamycin (Boehringer Mannheim) and incubated for
an additional 30 h at 37‡C in 5% CO2.
2.6. WGA-Sepharose precipitation and immunoblotting
Whole cell detergent lysates were prepared by solubilization in lysis
bu¡er (50 mM HEPES, pH 7.8, 300 mM NaCl, 1% NP-40 (Sigma),
1.2 mM EDTA, 5 mM MgCl2, 100 mM sodium vanadate, 10 mM
sodium pyrophosphate, 2 mM pepstatin, 0.5 trypsin inhibitory units
of aprotinin, 1 mM phenylmethylsulfonyl £uoride and 10 Wm leupep-
tin) and removal of insoluble material by centrifugation for 10 min in
a microcentrifuge at 4‡C. Clari¢ed lysates were incubated with 20 Wl
of WGA-Sepharose (Pharmacia) at 4‡C with rotation overnight. The
WGA-Sepharose complexes were washed three times with lysis bu¡er
and analyzed by sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE) and immunoblotting with the monoclonal 8D5
antibody speci¢c to L-dystroglycan or the polyclonal Sheep 172 anti-
body speci¢c to K-dystroglycan. Additionally, cell culture media were
collected from cell monolayers and incubated with WGA-Sepharose.
The WGA-Sepharose complexes were washed three times with lysis
bu¡er and analyzed by SDS^PAGE and immunoblotting with the
monoclonal 8D5 antibody speci¢c to L-dystroglycan or the polyclonal
Sheep 172 antibody speci¢c to K-dystroglycan. For immunoblotting,
proteins were visualized using enhanced chemiluminescence (Pierce).
2.7. Immunocytochemical staining and £uorescence microscopy
Cells grown on glass cover slips in the presence or absence of
tunicamycin were ¢xed and permeabilized in 2% paraformaldehyde/
0.2% Triton X-100 in phosphate-bu¡ered saline (PBS) for 5 min at
room temperature. The cells were blocked with 2% BSA in PBS and
then incubated with monoclonal 8D5 (dilution 1:1000) or polyclonal
Sheep 005 (dilution 1:500) primary antibodies. Primary antibodies
were detected with £uorescently tagged secondary antibodies (Jackson
Immunoresearch) used at a dilution of 1:250. Cells were imaged using
a Bio-Rad MRC-1024ES laser scanning confocal microscope.
3. Results and discussion
We prepared a CMV expression vector encoding full length
rabbit dystroglycan. This construct is predicted to encode an
895 amino acid precursor protein [28]. The site of cleavage on
the dystroglycan propeptide has been proposed to be on the
C-terminal of residue 653, such that the N-terminus of L-dys-
troglycan begins with Ser-654 [22,31]. However, to date there
is no biochemical evidence for the existence of this precursor
propeptide. L-Dystroglycan contains a transmembrane do-
main, while K-dystroglycan is secreted and held at the extra-
cellular face of the membrane via non-covalent associations
with the extracellular portion of L-dystroglycan.
We used a mammalian cell expression system to determine
whether we could detect the presence of the dystroglycan pre-
cursor propeptide. Toward this end, we transfected CHO cells
with dystroglycan cDNA encoding the precursor peptide.
Thirty hours post-transfection, we analyzed cellular lysates
by immunoblotting with a monoclonal antibody speci¢c to
L-dystroglycan (L-DG) (Fig. 1A) or a polyclonal antibody
which recognizes K-dystroglycan (K-DG) (Fig. 1A). Both of
these antibodies recognize amino acid epitopes in dystrogly-
can, and they are not directed against sites in the protein
which contain oligosaccharide. The very broad appearance
of the processed K-dystroglycan band is characteristic of the
high degree of carbohydrate addition to K-dystroglycan (Fig.
1A). It is also interesting to note that the mature form of K-
dystroglycan migrates at a lower molecular weight than the
156 kDa form of K-dystroglycan found in skeletal muscle;
thus carbohydrate modi¢cation contributes less to the overall
mass of K-dystroglycan expressed in cultured CHO cells. We
also observed two bands at approximately 150 and 160 kDa
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that were recognized by K- and L-dystroglycan antibodies. To
evaluate the extent of N-linked glycosylation of both the ma-
ture and propeptide forms of dystroglycan, cell extracts were
subjected to enzymatic deglycosylation using PNGaseF. As
shown in Fig. 1A, we observed an increase in mobility in
SDS gels in both L-dystroglycan and K-dystroglycan following
treatment with PNGaseF. This result con¢rms that K- and L-
dystroglycan are recipients of N-linked glycosylation in this
expression system. The broad appearance of K-dystroglycan
remains after PNGaseF treatment, suggesting that O-linked
glycosylation is contributing to the smeared staining pattern
of this band. Interestingly, the precursor peptide appeared as
a doublet in untreated samples, and the upper band (160 kDa)
shifted down to the size of the lower band (150 kDa) after
deglycosylation (Fig. 1A). This result indicates that the pre-
cursor peptide acquires N-linked oligosaccharides prior to the
cleavage event. The data demonstrate that the 160 kDa pre-
cursor propeptide is processed into a 43 kDa protein (L-dys-
troglycan) and a 120 kDa protein (K-dystroglycan). The fact
that both the monoclonal L-dystroglycan and the polyclonal
K-dystroglycan antibodies recognize the precursor peptide as
well as their respective cleaved subunits veri¢es these ¢ndings.
Recent reports have demonstrated that RT4 schwannoma
[32] and bovine aortic endothelial [33] cells secrete a soluble
form of K-dystroglycan into the culture medium. Neither of
these reports provided data which would explain why K-dys-
troglycan was released into the medium, rather than being
anchored securely at the extracellular face of the plasma mem-
brane via associations with L-dystroglycan. The BIO14.6 ham-
ster is a dystrophic animal model for LGMD, with a de¢ned
mutation in the N-sarcoglycan gene that results in the loss of
the entire sarcoglycan complex at the sarcolemma [34]. Recent
studies of the BIO14.6 hamster from our laboratory and
others demonstrate that the sarcoglycan complex is required
for stable association of K-dystroglycan at the membrane [14^
Fig. 2. Tunicamycin treatment inhibits tra⁄cking of L-dystroglycan to the surface plasma membrane. (A) Prevention of N-linked glycosylation
does not block cleavage of the dystroglycan precursor. CHO cells were transfected with the K/L-dystroglycan construct and grown in the ab-
sence (3) or presence (+) of tunicamycin, as detailed in Section 2. Whole cell lysates were analyzed by immunoblotting using antibodies di-
rected against L-dystroglycan (8D5). The presence of L-dystroglycan in tunicamycin-treated cells indicates that N-linked glycosylation is not nec-
essary for cleavage of the K/L-dystroglycan precursor. Tunicamycin e⁄ciently blocks N-linked glycosylation, as shown by the shift in molecular
mass of L-dystroglycan. (B) CHO cells expressing the K/L-dystroglycan construct were grown in the presence (+) or absence (3) of tunicamycin.
Cells were ¢xed with paraformaldehyde and analyzed by immuno£uorescence for the expression of L-dystroglycan (upper panels) using antibod-
ies against L-dystroglycan (8D5). The cells were viewed in the same focal planes using DIC in order to image the cell borders (lower panels).
Fig. 1. N-linked glycosylation does not a¡ect cleavage of the dystro-
glycan precursor. A: Post-translational processing of dystroglycan
was examined using CHO cells transiently transfected with a plas-
mid encoding the K/L-dystroglycan propeptide. Cellular lysates were
treated with the N-glycosidase, PNGaseF and subsequently exam-
ined by immunoblotting with monoclonal antibodies against L-dys-
troglycan (L-DG, 8D5) or polyclonal antibodies against K-dystrogly-
can (K-DG, Sheep 172). Control, untreated lysates (3) are shown
for comparison. The dystroglycan precursor polypeptide (K/L-DG
precursor) is detected by both the K-DG and L-DG antibodies. Mo-
lecular size standards are indicated on the left (U103 Da). B: The
mature form of K-dystroglycan is secreted into the cell culture me-
dia. Detergent extracts from CHO cells transiently transfected with
plasmid encoding the K/L-dystroglycan propeptide were incubated
with WGA-Sepharose to precipitate dystroglycan (lane 1). At the
same time, WGA-Sepharose was used to enrich dystroglycan that
may have been released from the CHO cells into the cell culture me-
dia (lane 2). Proteins bound to the WGA-Sepharose were analyzed
by Western blotting with antibodies to K-dystroglycan. Mature K-
dystroglycan was secreted into the culture media (lane 2), however,
the K/L-dystroglycan precursor remained in the cellular lysate (lane
1). Molecular size standards are indicated on the left (U103 Da).
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16]. Therefore, we speculate that K-dystroglycan may not be
held securely at the membrane in cultured non-muscle cells
which lack the sarcoglycan complex.
We looked for the presence of soluble K-dystroglycan in the
conditioned medium of our CHO cells expressing dystrogly-
can. WGA-Sepharose precipitates from whole cell detergent
extract (Fig. 1B, lane 1) and conditioned cell culture medium
(Fig. 1B, lane 2) from cells expressing dystroglycan were an-
alyzed by immunoblotting with the polyclonal antibody
against K-dystroglycan (K-DG). Both the precursor peptide
and the mature form of K-dystroglycan were readily precipi-
tated by the WGA-Sepharose from the cell lysate. In contrast,
only the fully processed form of K-dystroglycan was detected
in the culture medium. This result is not surprising, because
the dystroglycan precursor peptide contains the transmem-
brane domain, and therefore we would not expect it to be
competent for secretion.
To further evaluate the contribution of N-linked oligosac-
charide addition to the maturation and tra⁄cking of dystro-
glycan, we performed experiments using tunicamycin. Tunica-
mycin is a glycosylation inhibitor that blocks the transfer of
dolichol pyrophosphate precursor to asparagine in the ¢rst
step of N-linked oligosaccharide addition. In Fig. 2A, cells
expressing dystroglycan were left untreated (3) or treated
(+) with tunicamycin. Equal quantities of protein were loaded
onto SDS^polyacrylamide gels and then analyzed by immu-
noblot using antibodies against L-dystroglycan. Tunicamycin
treatment resulted in a nearly complete block in N-linked gly-
cosylation as evidenced by the smaller molecular weight of L-
dystroglycan (Fig. 2A). Interestingly, cleavage of the precur-
sor peptide can proceed in the absence of N-linked glycosyl-
ation, as evidenced by the presence of the smaller non-glyco-
sylated form of L-dystroglycan, which is detected by the L-
dystroglycan monoclonal antibody (Fig. 2A).
Finally, to con¢rm that N-linked oligosaccharide addition
was essential for successful biosynthesis and tra⁄cking of K-
and L-dystroglycan, we examined the cellular localization of
these proteins by confocal microscopy. CHO cells expressing
dystroglycan were grown on glass cover slips in the absence or
presence of tunicamycin. Using immuno£uorescence with the
L-dystroglycan antibody, we demonstrate that L-dystroglycan
was localized to the peripheral cell membranes when the cells
were grown in the absence of tunicamycin (Fig. 2B). The cells
grown in the presence of tunicamycin exhibited a dramatic
relocalization of L-dystroglycan to intracellular perinuclear
structures (Fig. 2B). K-Dystroglycan localization was also cy-
tosolic by the treatment with tunicamycin (data not shown).
The cells were also imaged using di¡erential interference con-
trast (DIC) optics to clearly delineate the cell borders (Fig.
2B). Tunicamycin treatment did not a¡ect the gross appear-
ance, cell growth or viability of the transfected CHO cells.
These results are consistent with the idea that N-linked gly-
cosylation is a requisite step in the sequence of events for
normal processing and cell surface localization of the K- and
L-dystroglycan subunits.
We have employed a heterologous cell system to study the
biosynthesis and maturation of the K- and L-dystroglycan
propeptide. First, we provide evidence for the existence of
the uncleaved K- and L-dystroglycan propeptide and we
have summarized these ¢ndings in Fig. 3. We show that this
160 kDa precursor is processed into K- and L-dystroglycan
(120 kDa and 43 kDa, respectively). The precursor polypep-
tide has never been observed in native tissue, likely because it
is rapidly cleaved into K- and L-dystroglycan. Our overexpres-
sion of dystroglycan in cultured CHO cells has enabled us to
‘catch’ the glycosylated and non-glycosylated forms of the
dystroglycan precursor protein prior to cleavage. We have
also addressed what role N-linked oligosaccharide addition
plays in the sequence of events that are required for successful
dystroglycan maturation. We provide convincing evidence
that N-linked glycosylation is not an absolute prerequisite
for cleavage, because the precursor peptide is readily cleaved
when N-linked glycosylation is blocked by tunicamycin. On
the other hand, N-linked glycosylation is required for the cell
surface localization of both K- and L-dystroglycan. In the
future, we hope to use this model system to study the binding
potential of K-dystroglycan to various extracellular matrix
components, as well as the association of L-dystroglycan
with the cytoskeletal proteins, dystrophin and utrophin. We
also expect such studies to reveal how speci¢c post-transla-
tional modi¢cations of K- and L-dystroglycan modulate pro-
tein^protein interactions.
In recent years, genetic approaches have provided enor-
mous advances in our understanding of the central role played
by the DGC in muscle physiology. We now understand that
mutations in various components of the DGC can independ-
Fig. 3. Biosynthetic intermediates of dystroglycan. A: Schematic de-
piction of the domain organization of the K/L-dystroglycan propep-
tide. The dystroglycan propeptide has an N-terminal signal sequence
(ss), a mucin-like region, and a single transmembrane domain (TM).
Amino acid numbers are given below the diagram. The K/L-dystro-
glycan propeptide consists of 895 amino acid residues and is pre-
dicted to have a core molecular mass of 97 kDa. Proteolytic cleav-
age of the dystroglycan propeptide occurs after residue 653 (dashed
line) to produce K- and L-dystroglycan subunits. K-Dystroglycan
undergoes signi¢cant post-translational modi¢cations and the molec-
ular mass of this protein can vary between 120 and 156 kDa, de-
pending on the tissue from which it is isolated. B: Representative
structure of the mature K- and L-dystroglycan polypeptides. K-Dys-
troglycan is depicted as a dumb-bell-shaped structure, with N- and
C-terminal globular domains separated by an extended mucin-like
region. Extensive O-linked glycosylation (a) within this region likely
mediates interactions with laminin in the extracellular matrix. Poten-
tial sites for attachment of glycosaminoglycan chains are indicated
with hexagons and sites for N-linked carbohydrate modi¢cation are
represented with branches. K-Dystroglycan non-covalently interacts
with L-dystroglycan, which resides within the cellular membrane. In
turn, the C-terminus of L-dystroglycan is associated with dystro-
phin, thereby completing the structural link between the extracellu-
lar matrix and the intracellular cytoskeleton.
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ently, and to varying degrees, result in structural and func-
tional de¢cits in the DGC, which inevitably lead to muscle
¢ber damage and necrosis. Dystroglycan is notably absent
from the list of DGC members which have been genetically
linked to forms of human muscular dystrophy. Recently, a
dystroglycan knock out mouse has been reported to su¡er
an early embryonic lethal phenotype, suggesting that by way
of analogy, mutations in dystroglycan may be deleterious in
humans [17]. The role of dystroglycan in normal muscle func-
tion must await the generation of a conditional allele of dys-
troglycan, which can be turned o¡ in muscle under controlled
conditions.
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